Longitudinal multi-omics study of palbociclib resistance in HR-positive/HER2-negative metastatic breast cancer
Longitudinal multi-omics study of palbociclib resistance in HR-positive/HER2-negative metastatic breast cancer is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Longitudinal multi-omics study of palbociclib resistance in HR-positive/HER2-negative metastatic breast cancer have?
Longitudinal multi-omics study of palbociclib resistance in HR-positive/HER2-negative metastatic breast cancer has 56 citations in the OpenAlex counts ScholarIQ stores.
When was Longitudinal multi-omics study of palbociclib resistance in HR-positive/HER2-negative metastatic breast cancer published?
Longitudinal multi-omics study of palbociclib resistance in HR-positive/HER2-negative metastatic breast cancer has 2023 year in the ScholarIQ index.
What is the open-access status of Longitudinal multi-omics study of palbociclib resistance in HR-positive/HER2-negative metastatic breast cancer?
Longitudinal multi-omics study of palbociclib resistance in HR-positive/HER2-negative metastatic breast cancer has gold oa status in the ScholarIQ index.
What is the DOI of Longitudinal multi-omics study of palbociclib resistance in HR-positive/HER2-negative metastatic breast cancer?
The DOI for Longitudinal multi-omics study of palbociclib resistance in HR-positive/HER2-negative metastatic breast cancer is on the source record.
What is the PMID of Longitudinal multi-omics study of palbociclib resistance in HR-positive/HER2-negative metastatic breast cancer?
The PMID for Longitudinal multi-omics study of palbociclib resistance in HR-positive/HER2-negative metastatic breast cancer is on the source record.
What is the OpenAlex record for Longitudinal multi-omics study of palbociclib resistance in HR-positive/HER2-negative metastatic breast cancer?
The OpenAlex for Longitudinal multi-omics study of palbociclib resistance in HR-positive/HER2-negative metastatic breast cancer is on the source record.